Revvity Shares Decline Despite Launch of Transcribe AI Solution
China Microarray Market Analysis by Product, Application, and End-user, Forecast to 2031 - Thermo Fisher Scientific, Illumina, Merck, Revvity, and Agilent Technologies Dominate the Competitive Landscape
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
Revvity Highlights Its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
Revvity Earnings Preview: What to Expect
Revvity Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $135
Express News | Revvity Inc : Leerink Partners Raises Target Price to $135 From $130
Revvity To Go Ex-Dividend On October 18th, 2024 With 0.07 USD Dividend Per Share
October 16th (Eastern Time) - $Revvity(RVTY.US)$ is trading ex-dividend on October 18th, 2024.Shareholders of record on October 18th, 2024 will receive 0.07 USD dividend per share on November 8th, 202
Is Now An Opportune Moment To Examine Revvity, Inc. (NYSE:RVTY)?
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $140
News Highlights: Top Company News of the Day - Tuesday at 11 AM ET
Revvity Analyst Ratings
Barclays Upgrades Revvity(RVTY.US) to Buy Rating, Raises Target Price to $140
Barclays Upgrades Revvity to Overweight, Price Target Is $140
Revvity Ramps Up R&D Spending Since PerkinElmer Split -- WSJ
Australia & New Zealand Research Antibodies Market Report 2024-2030, With Leading Players Abcam, BD, Merck, Lonza, Cell Signaling Technology, F. Hoffmann-La Roche, Agilent Technologies, Revvity & More
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
Nephron Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $130